BAMBI elimination enhances alternative TGF-b signaling and glomerular dysfunction in diabetic mice

Diabetes

Volumn 64, Issue 6, 2015, Pages 2220-2233

  Fan, Ying ^a,b   Li, Xuezhu ^a   Xiao, Wenzhen ^a   Fu, Jia ^a   Harris, Ray C ^c   Lindenmeyer, Maja ^d   Cohen, Clemens D ^d   Guillot, Nicolas ^a   Baron, Margaret H ^a   Wang, Niansong ^b   Lee, Kyung ^a   He, John C ^a,e   Schlondorff, Detlef ^a   Chuang, Peter Y ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN AND ACTIVIN MEMBRANE BOUND INHIBITOR; HISTONE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; SMAD1 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ANGIOPOIETIN 1; ANGPT1 PROTEIN, MOUSE; BAMBI PROTEIN, MOUSE; MEMBRANE PROTEIN; SMAD1 PROTEIN, MOUSE; SMAD5 PROTEIN, MOUSE; VEGFR2 PROTEIN, MOUSE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; GLOMERULAR DYSFUNCTION; GLOMERULUS; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY CORTEX; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; GENETICS; IN VITRO STUDY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANGIOPOIETIN-1; ANIMALS; BLOTTING, WESTERN; HUMANS; IN VITRO TECHNIQUES; KIDNEY GLOMERULUS; MEMBRANE PROTEINS; MICE; SIGNAL TRANSDUCTION; SMAD1 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84954340345     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1397     Document Type: Article

References (58)

1. Østerby R. Early phases in the development of diabetic glomerulopathy. Acta Med Scand Suppl 1974;574:3-82.
2. Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003;52:1031-1035.
3. Sharma K, Ziyadeh FN. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Semin Nephrol 1997;17:80-92.
4. Ziyadeh FN. Mediators of diabetic renal disease: The case for tgf-Beta as the major mediator. J Am Soc Nephrol 2004;15(Suppl. 1):S55-S57.
5. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-beta by anti-TGFbeta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996;45:522-530.
6. Ziyadeh FN, Hoffman BB, Han DC, et al. Long- Term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000;97: 8015-8020.
7. Chen S, Iglesias-de la Cruz MC, Jim B, Hong SW, Isono M, Ziyadeh FN. Reversibility of established diabetic glomerulopathy by anti-TGF-beta antibodies in db/db mice. Biochem Biophys Res Commun 2003;300:16-22.
8. Massagué J. TGF-beta signal transduction. Annu Rev Biochem 1998;67: 753-791.
9. Li J, Qu X, Yao J, et al. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy. Diabetes 2010;59:2612-2624.
10. Wang A, Ziyadeh FN, Lee EY, et al. Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria. Am J Physiol Renal Physiol 2007;293:F1657-F1665.
11. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584.
12. Haneda M, Koya D, Kikkawa R. Cellular mechanisms in the development and progression of diabetic nephropathy: Activation of the DAG-PKC-ERK pathway. Am J Kidney Dis 2001;38(4 Suppl 1):S178-S181.
13. Lin CL, Wang FS, Kuo YR, et al. Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int 2006;69:1593-1600.
14. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R. Mitogenactivated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 1997;46:847-853.
15. Feliers D, Kasinath BS. Erk in kidney diseases. J Signal Transduct 2011; 2011:768512.
16. Sena CM, Pereira AM, Seiça R. Endothelial dysfunction - A major mediator of diabetic vascular disease. Biochim Biophys Acta 2013;1832:2216-2231.
17. Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA. Abnormal angiogenesis in diabetic nephropathy. Diabetes 2009;58:1471-1478.
18. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: A role for the glomerular endothelium? Diabetologia 2008;51:714-725.
19. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 2008;4:39-45.
20. Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011;60: 2354-2369.
21. Hodgin JB, Nair V, Zhang H, et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 2013;62:299-308.
22. Goumans MJ, Mummery C. Functional analysis of the TGFbeta receptor/Smad pathway through gene ablation in mice. Int J Dev Biol 2000;44:253-265.
23. Pardali E, ten Dijke P. Transforming growth factor-beta signaling and tumor angiogenesis. Front Biosci (Landmark Ed) 2009;14:4848-4861.
24. Seki T, Yun J, Oh SP. Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 2003;93:682-689.
25. Oh SP, Seki T, Goss KA, et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000;97:2626-2631.
26. Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Mol Cell 2008;31: 918-924.
27. Ren B, Deng Y, Mukhopadhyay A, et al. ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. J Clin Invest 2010;120:1217-1228.
28. Sumpio BE, Yun S, Cordova AC, et al. MAPKs (ERK1/2, p38) and AKT can be phosphorylated by shear stress independently of platelet endothelial cell adhesion molecule-1 (CD31) in vascular endothelial cells. J Biol Chem 2005;280: 11185-11191.
29. Holm TM, Habashi JP, Doyle JJ, et al. Noncanonical TGFb signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 2011; 332:358-361.
30. Guillot N, Kollins D, Gilbert V, et al. BAMBI regulates angiogenesis and endothelial homeostasis through modulation of alternative TGFβ signaling. PLoS One 2012;7:e39406.
31. Guillot N, Kollins D, Badimon JJ, Schlondorff D, Hutter R. Accelerated reendothelialization, increased neovascularization and erythrocyte extravasation after arterial injury in BAMBI-/- mice. PLoS One 2013;8:e58550.
32. Onichtchouk D, Chen YG, Dosch R, et al. Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 1999;401:480-485.
33. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13:1324-1332.
34. Yan X, Lin Z, Chen F, et al. Human BAMBI cooperates with Smad7 to inhibit transforming growth factor-beta signaling. J Biol Chem 2009;284:30097-30104.
35. Chen J, Bush JO, Ovitt CE, Lan Y, Jiang R. The TGF-beta pseudoreceptor gene Bambi is dispensable for mouse embryonic development and postnatal survival. Genesis 2007;45:482-486.
36. Fraser ST, Hadjantonakis AK, Sahr KE, et al. Using a histone yellow fluorescent protein fusion for tagging and tracking endothelial cells in ES cells and mice. Genesis 2005;42:162-171.
37. Feng M, Whitesall S, Zhang Y, Beibel M, D'Alecy L, DiPetrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. Am J Hypertens 2008;21:1288-1291.
38. Yuen PS, Dunn SR, Miyaji T, Yasuda H, Sharma K, Star RA. A simplified method for HPLC determination of creatinine in mouse serum. Am J Physiol Renal Physiol 2004;286:F1116-F1119.
39. Gu L, Dai Y, Xu J, et al. Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1- Associated nephropathy. AIDS 2013;27:1091-1098.
40. Mallipattu SK, Liu R, Zhong Y, et al. Expression of HIV transgene aggravates kidney injury in diabetic mice. Kidney Int 2013;83:626-634.
41. Chuang PY, Dai Y, Liu R, et al. Alteration of forkhead box O (foxo4) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One 2011;6: E23566.
42. Takemoto M, Asker N, Gerhardt H, et al. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol 2002;161:799-805.
43. Cohen CD, Frach K, Schlöndorff D, Kretzler M. Quantitative gene expression analysis in renal biopsies: A novel protocol for a high- Throughput multicenter application. Kidney Int 2002;61:133-140.
44. Zhao HJ, Wang S, Cheng H, et al. Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. J Am Soc Nephrol 2006;17:2664-2669.
45. Salles C II, Monkman JH, Ahnstrom J, Lane DA, Crawley JT. Vessel wall bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI) contributes to hemostasis and thrombus stability. Blood 2014;123:2873-2881.
46. Schlöndorff D. Choosing the right mouse model for diabetic nephropathy. Kidney Int 2010;77:749-750.
47. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R. Activation of mitogen- Activated protein kinase cascade in diabetic glomeruli and mesangial cells cultured under high glucose conditions. Kidney Int Suppl 1997;60:S66-S69.
48. Xie L, Law BK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia 2004;6: 603-610.
49. Morikawa M, Koinuma D, Tsutsumi S, et al. ChIP-seq reveals cell typespecific binding patterns of BMP-specific Smads and a novel binding motif. Nucleic Acids Res 2011;39:8712-8727.
50. Simon M, Gröne HJ, Jöhren O, et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 1995;268:F240-F250.
51. Jin J, Sison K, Li C, et al. Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function. Cell 2012; 151:384-399.
52. Tufro A, Norwood VF, Carey RM, Gomez RA. Vascular endothelial growth factor induces nephrogenesis and vasculogenesis. J Am Soc Nephrol 1999;10: 2125-2134.
53. Satchell SC, Braet F. Glomerular endothelial cell fenestrations: An integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol 2009; 296:F947-F956.
54. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008;358:1129-1136.
55. Sison K, Eremina V, Baelde H, et al. Glomerular structure and function require paracrine, not autocrine, VEGF-VEGFR-2 signaling. J Am Soc Nephrol 2010;21:1691-1701.
56. Brosius FC 3rd, Alpers CE. New targets for treatment of diabetic nephropathy: What we have learned from animal models. Curr Opin Nephrol Hypertens 2013;22:17-25.
57. Advani A, Gilbert RE. The endothelium in diabetic nephropathy. Semin Nephrol 2012;32:199-207.
58. Dessapt-Baradez C, Woolf AS, White KE, et al. Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease. J Am Soc Nephrol 2014;25:33-42.